Terms: = Prostate cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
11 results:
1. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract] [Full Text] [Related]
2. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
3. Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells.
Souza DS; Lombardi APG; Vicente CM; Lucas TFG; Erustes AG; Pereira GJS; Porto CS
Mol Cell Endocrinol; 2019 Mar; 483():11-23. PubMed ID: 30660702
[TBL] [Abstract] [Full Text] [Related]
4. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant prostate cancer.
Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
[TBL] [Abstract] [Full Text] [Related]
5. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
[TBL] [Abstract] [Full Text] [Related]
6. xpo1/crm1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract] [Full Text] [Related]
7. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer.
Mendonca J; Sharma A; Kim HS; Hammers H; Meeker A; De Marzo A; Carducci M; Kauffman M; Shacham S; Kachhap S
Oncotarget; 2014 Aug; 5(15):6102-12. PubMed ID: 25026284
[TBL] [Abstract] [Full Text] [Related]
8. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating crm1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract] [Full Text] [Related]
9. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
Iio A; Takagi T; Miki K; Naoe T; Nakayama A; Akao Y
Biochim Biophys Acta; 2013 Oct; 1829(10):1102-10. PubMed ID: 23932921
[TBL] [Abstract] [Full Text] [Related]
10. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and crm1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract] [Full Text] [Related]
11. Experiences of follow-up after treatment in patients with prostate cancer: a qualitative study.
O'Brien R; Rose PW; Campbell C; Weller D; Neal RD; Wilkinson C; Watson EK;
BJU Int; 2010 Oct; 106(7):998-1003. PubMed ID: 20230391
[TBL] [Abstract] [Full Text] [Related]
